Exosome-mediated MEK1 silencing is a promising approach against triple negative breast cancer regression

[Excerpt] Introduction: Breast cancer is a major public health problem worldwide being the most diagnosed cancer in women [1] . Triple negative breast cancer (TNBC) represents 10-20% of all breast cancers and is characterized by the absence of hormone receptors (progesterone and estrogen) and lack of expression of epidermal growth factor receptor 2. Furthermore, it is also described to have poor prognosis due to its propensity to metastasize to visceral organs early in the clinical course [2–4] . In accordance with the lack of recurrently altered targets at the genomic level, there is a shortage of approved targeted agents for TNBC, remaining cytotoxic chemotherapy the mainstay of treatment. [...]
This work was supported by by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UID/BIO/04469/2020 unit. Débora Ferreira is recipient of a fellowship supported by a doctoral advanced training (call NORTE-69-2015-15) funded by the European Social Fund under the scope of Norte2020 - Programa Operacional Regional do Norte. Débora Ferreira also acknowledges “Liga Portuguesa contra o cancro - Núcleo Regional do Norte (LPCC-NRN) “for her current fellowship.
info:eu-repo/semantics/publishedVersion